Share-based Payment Arrangement, Expense of Korro Bio, Inc. from 30 Sep 2018 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Korro Bio, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2018 to 30 Sep 2025.
  • Korro Bio, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,825,000, a 43% increase year-over-year.
  • Korro Bio, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $6,941,000, a 60% increase year-over-year.
  • Korro Bio, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $4,462,000, a 87% increase from 2023.
  • Korro Bio, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $2,381,000, a 109% increase from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Korro Bio, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $6,941,000 $1,825,000 +$552,000 +43% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $6,389,000 $1,998,000 +$1,031,000 +107% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $5,358,000 $1,761,000 +$896,000 +104% 01 Jan 2025 31 Mar 2025 10-Q 07 May 2025 2025 Q1
Q4 2024 $4,462,000 $1,357,000 +$130,000 +11% 01 Oct 2024 31 Dec 2024 10-K 18 Mar 2025 2024 FY
Q3 2024 $4,332,000 $1,273,000 +$869,000 +215% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $3,463,000 $967,000 +$566,000 +141% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q2
Q1 2024 $2,897,000 $865,000 +$516,000 +148% 01 Jan 2024 31 Mar 2024 10-Q 07 May 2025 2025 Q1
Q4 2023 $2,381,000 $1,227,000 +$15,512,000 01 Oct 2023 31 Dec 2023 10-K 18 Mar 2025 2024 FY
Q3 2023 $13,131,000 $404,000 -$5,191,000 -93% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $7,940,000 $401,000 -$4,163,000 -91% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $3,777,000 $349,000 -$4,917,000 -93% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q4 2022 $1,140,000 $14,285,000 01 Oct 2022 31 Dec 2022 10-K 26 Mar 2024 2023 FY
Q3 2022 $5,595,000 -$291,000 -4.9% 01 Jul 2022 30 Sep 2022 10-Q 02 Nov 2023 2023 Q3
Q2 2022 $4,564,000 -$1,525,000 -25% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $5,266,000 +$655,000 +14% 01 Jan 2022 31 Mar 2022 10-Q 12 May 2023 2023 Q1
Q3 2021 $5,886,000 +$3,243,000 +123% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $6,089,000 +$3,678,000 +153% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $4,611,000 +$2,447,000 +113% 01 Jan 2021 31 Mar 2021 10-Q 04 May 2022 2022 Q1
Q3 2020 $2,643,000 +$1,718,000 +186% 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021 2021 Q3
Q2 2020 $2,411,000 +$929,000 +63% 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q2
Q1 2020 $2,164,000 01 Jan 2020 31 Mar 2020 10-Q 13 May 2021 2021 Q1
Q3 2019 $925,000 +$823,000 +807% 01 Jul 2019 30 Sep 2019 10-Q 16 Nov 2020 2020 Q3
Q2 2019 $1,482,000 01 Apr 2019 30 Jun 2019 10-Q 12 Aug 2020 2020 Q2
Q3 2018 $102,000 01 Jul 2018 30 Sep 2018 10-Q 18 Nov 2019 2019 Q3

Korro Bio, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $4,462,000 +$2,081,000 +87% 01 Jan 2024 31 Dec 2024 10-K 18 Mar 2025 2024 FY
2023 $2,381,000 +$1,241,000 +109% 01 Jan 2023 31 Dec 2023 10-K 18 Mar 2025 2024 FY
2022 $1,140,000 01 Jan 2022 31 Dec 2022 10-K 26 Mar 2024 2023 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.